SCHEMBL5401008

SCHEMBL5401008

CCOc1cccc(CCN(CCC(=O)O)C(=O)c2ccccc2-c2ccccc2C(=O)NCc2ccccc2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.52
KLKB1 P03952 1/20 0.44
KLK1 P06870 1/20 0.44
POLB P06746 2/20 0.44
HPGD P15428 3/20 0.44
KMT2A Q03164 1/20 0.44
CHRNB2 P17787 1/20 0.43
CHRNB4 P30926 1/20 0.43
CHRNA3 P32297 1/20 0.43
CHRNA4 P43681 1/20 0.43
LTB4R Q15722 1/20 0.43
LTB4R2 Q9NPC1 1/20 0.43
ROCK1 Q13464 2/20 0.43
ROCK2 O75116 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
NPSR1 Q6W5P4 1/20 0.42
ALDH1A1 P00352 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5416693 0.96 RAB9A (0.48) RAB9AKLKB1KLK1POLBHPGD
SCHEMBL4929716 0.95 RAB9A (0.47) RAB9AKLKB1KLK1POLBHPGD
SCHEMBL5399721 0.95 RAB9A (0.54) RAB9AKLKB1KLK1POLBHPGD
SCHEMBL5394436 0.95 RAB9A (0.47) RAB9AKLKB1KLK1POLBHPGD
SCHEMBL5402665 0.95 RAB9A (0.61) RAB9APOLBHPGDKMT2AROCK1
SCHEMBL5398729 0.94 RAB9A (0.50) RAB9AKLKB1KLK1POLBHPGD
SCHEMBL5394825 0.93 NR1H4 (0.46) RAB9AKLKB1KLK1POLBHPGD
SCHEMBL5397730 0.93 RAB9A (0.49) RAB9AKLKB1KLK1HPGDKMT2A
SCHEMBL5394068 0.93 RAB9A (0.49) RAB9AKLKB1KLK1POLBHPGD
SCHEMBL5411805 0.93 RAB9A (0.47) RAB9AKLKB1KLK1POLBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7285680-B2 β-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-10-23 US disclosed
US-20050256160-A1 Beta-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2005-11-17 US disclosed
EP-1533294-A1 BETA-ALANINE DERIVATIVE AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256160-A1 Beta-alanine derivatives and the use thereof TGFB1, PML, APOB RAB9A 3132/4885KLKB1 442/4885KLK1 652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.